eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

vol. 43
Clinical immunology

Expression of E-cadherin, β-catenin, and epithelial membrane antigen does not predict survival in patients with high-risk non-muscle-invasive bladder cancer

Sławomir Poletajew, Łukasz Fus, Tomasz Ilczuk, Piotr Wojcieszak, Małgorzata Sękowska, Wojciech Krajewski, Aleksander Wasiutyński, Barbara Górnicka, Piotr Radziszewski

(Centr Eur J Immunol 2018; 43 (4): 421-427)
Online publish date: 2018/12/31
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The aim of the study
was to validate the value of E-cadherin and β-catenin expression and to test an alternative prognostic marker, epithelial membrane antigen (EMA).

Material and methods
Forty-nine consecutive patients with primary stage T1 non-muscle-invasive bladder cancer (NMIBC) were enrolled in this study. Tissue specimens were stained with the following mouse anti-human antibodies: anti-E-cadherin, anti-β-catenin, and anti-EMA. Reaction intensity within cancer cells was assessed according to the immunoreactive score (IRS). Finally, the association between the expression of selected proteins and patient survival was assessed.

The mean follow-up was 34.8 months. Recurrence-free survival, progression-free survival, and overall survival (OS) were 47.5%, 72.5%, and 72.5%, respectively. Differences in the IRS for β-catenin and EMA were found clinically, but were not statistically significant in prediction of the risk of disease progression (p > 0.05). No difference in protein expression was observed regarding the risk of recurrence, OS, or cancer-specific mortality (p > 0.05). Stratification of patients based on the IRS into three groups (poor, moderate, and intensive reaction) failed to identify a prognostic marker among the tested proteins (p > 0.05).

Expression of E-cadherin, β-catenin, and EMA cannot reliably predict survival in patients with high-risk NMIBC. Further searches are needed to identify tissue markers of progression and recurrence in NMIBC.


bladder cancer, disease progression, immunohistochemistry, recurrence, survival

van den Bosch S, Witjes JA (2011): Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 60: 493-500.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. (2006): Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-75.
Fernandez-Gomez J, Madero R, Solsona E, et al. (2009): Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182: 2195-203.
Ali-El-Dein B, Al-Marhoon MS, Abdel-Latif M, et al. (2011): Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder. Urol Ann 3: 127-132.
Hautmann RE, Volkmer BG, Gust K (2009): Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 27: 347-351.
May M, Bastian PJ, Brookman-May S, et al. (2011): Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scand J Urol Nephrol 45: 251-257.
Cheng L, Davison DD, Adams J, et al. (2014): Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 89: 73-111.
Sun W, Herrera GA (2002): E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum Pathol 33: 996-1000.
Lee JM, Dedhar S, Kalluri R, Thompson EW (2006): The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981.
Erdemir F, Ozcan F, Kilicaslan I, et al. (2007): The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol 39: 1031-1037.
Khorrami MH, Hadi M, Gharaati MR, et al. (2012): E-cadherin expression as a prognostic factor in transitional cell carcinoma of the bladder after transurethral resection. Urol J 9: 581-585.
Muramaki M, Miyake H, Terakawa T, et al. (2012): Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol 30: 161-166.
Liu B, Miyake H, Nishikawa M, et al. (2015): Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection. Urol Oncol 33: 110 e11-8.
Mahnken A, Kausch I, Feller AC, et al. (2005): E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. Oncol Rep 14: 1065-1070.
Raspollini MR, Luque RJ, Menendez CL, et al. (2016): T1 High Grade Bladder Carcinoma Outcome: The Role of P16, Topoisomerase-Ii Alpha, Survivin and E-Cadherin. Hum Pathol 57: 78-84.
Zhao J, Dong D, Sun L, et al. (2014): Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer. Int Braz J Urol 40: 179-189.
Breyer J, Gierth M, Shalekenov S, et al. (2016): Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma. World J Urol 34: 709-716.
Thoreson MA, Reynolds AB (2002): Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation 70: 583-589.
Hu X, Ruan Y, Cheng F, et al. (2011): p130Cas, E-cadherin and beta-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol 18: 630-637.
Shimazui T, Schalken JA, Giroldi LA, et al. (1996): Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 56: 4154-4158.
Schrier BP, Vriesema JL, Witjes JA, et al. (2006): The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol 50: 76-82.
Senol S, Yildirim A, Ceyran B, et al. (2015): Prognostic significance of survivin, beta-catenin and p53 expression in urothelial carcinoma. Bosn J Basic Med Sci 15: 7-14.
Clairotte A, Lascombe I, Fauconnet S, et al. (2006): Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 125: 119-126.
Kashibuchi K, Tomita K, Schalken JA, et al. (2006): The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol 49: 839-845.
Reis ST, Leite KR, Mosconi Neto A, et al. (2012): Immune expression of E-cadherin and alpha, beta and gamma-Catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas. Int Braz J Urol 38: 466-473.
Lin W, Liu X, Cen Y (2016): Diagnostic accuracy of epithelial membrane antigen for malignant effusions: a meta-analysis. Int J Biol Markers 31: e11-16.
Takashi M, Murase T, Kinjo T, et al. (1987): Epithelial membrane antigen as an immunohistochemical marker for transitional cell carcinoma of the urinary bladder. Urol Int 42: 170-175.
Asamoto M, Fukushima S, Oosumi H, et al. (1989): Immunohistochemical distribution of epithelial membrane antigen in bladder carcinomas as detected with a monoclonal antibody. Urol Res 17: 273-277. Ring KS, Karp F, Benson MC (1990): Enhanced detection of bladder cancer using the epithelial surface marker epithelial membrane antigen: a preliminary report. J Occup Med 32: 904-909.
Tanaka K, Takashi M, Miyake K, et al. (1994): Immunocytochemically demonstrated expression of epithelial membrane antigen and carcinoembryonic antigen by exfoliated urinary cells in patients with bladder cancer. Urol Int 52: 140-144.
Attallah AM, El-Far M, Abdallah SO, et al. (2015): Combined use of epithelial membrane antigen and nuclear matrix protein 52 as sensitive biomarkers for detection of bladder cancer. Int J Biol Markers 30: e407-413.
Lambert EH, Pierorazio PM, Olsson CA, et al. (2007): The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 100: 33-36.
Margel D, Tal R, Golan S, et al. (2007): Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guerin immunotherapy. Urology 69: 78-82.
Pansadoro V, Emiliozzi P, de Paula F, et al. (2002): Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59: 227-231.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe